Back to the main directory
EarningsReview / Equity
- EMIS Group - On track by Edison Investment Research
- S&U - Experienced specialist lender performs well by Edison Investment Research
- Video games in the spotlight by BNP Paribas Exane
- Redact Reduce by BNP Paribas Exane
- The Good, The Bad, And The Unknown by BNP Paribas Exane
- Haid Group (002311 CH) by HSBC
- Sunner Development (002299 CH) by HSBC
- A boost that will fade by BNP Paribas Exane
- Weak set of H1 results, risks ahead by BNP Paribas Exane
- Aker Solutions - Awaiting the cash splash by Danske Bank Equity Research
- Scatec - Investment case remains intact by Danske Bank Equity Research
- Guard Therapeutics - First important trial update due already next quarter by Danske Bank Equity Research
- Hennes & Mauritz (Hold, TP: SEK125.00) - Weak Q3 results by DnB Markets
- Atlas Copco (Hold, TP: SEK115.00) - FX lifts estimates, but still a HOLD by DnB Markets
- Bonava (Buy, TP: SEK50.00) - Negative sentiment, but deep value by DnB Markets
- Peab (Buy, TP: SEK74.00) - Energy costs set to hit Q3 by DnB Markets
- Tele2 (Buy, TP: SEK120.00) - Too attractive to ignore by DnB Markets
- Hennes & Mauritz (Hold, TP: SEK105.00) - Q3 no turning point by DnB Markets
- Fortnox Minor model adjustments by DnB Markets
- Baillie Gifford US Growth Trust - Emerging from the eye of the storm? by Edison Investment Research
- Ergomed - Poised for a strong FY22 by Edison Investment Research
- Kendrion - CMD confirms strategic direction and targets by Edison Investment Research
- Scandion Oncology - CORIST part 2 top-line data by Edison Investment Research
- OPDENERGY - 1H22 Results: No change to bullish view on top-pick; Buy reiterated by JB Capital Markets
- Elisa (Sell, TP: EUR46.00) - Mind the (narrow yield) gap by DnB Markets